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A B S T R A C T
Multiple myeloma (MM) is characterised by destructive lytic bone disease, caused by induction of bone re-
sorption and impaired bone formation. Our understanding of the molecular mechanisms responsible for os-
teoblast suppression, are limited. Using the 5T2MM murine model of MM we have previously shown that
suppression of the activity of a known inhibitor of bone formation Dikkopf-1 (Dkk1) prevents the development of
lytic bone disease. Here we have demonstrated that another potential inhibitor of bone formation, sclerostin
domain containing 1 (Sostdc1) is expressed at low levels in MM and osteoblast lineage cells when these cells are
grown separately in cell culture but its expression is signiﬁcantly induced in both cell types when these cells are
in contact. The distribution of Sostdc1 staining in bones inﬁltrated with 5TGM1 myeloma cells in vivo suggested
its presence in both myeloma and osteoblast lineage populations when in close proximity. We have also shown
that recombinant Sostdc1 inhibits both bone morphogenic proteins (BMP2 and 7) and Wnt signalling in primary
osteoblasts and suppresses diﬀerentiation of these cells. Together, these ﬁndings suggest that Sostdc1 expression
in 5TGM1-inﬁltrated bones as a result of the interaction between myeloma and osteoblast lineage populations,
could result in suppression of osteoblast diﬀerentiation.
1. Introduction
Recently, studies have shown that multiple myeloma (MM) cells
arriving in bone occupy niches, where they interact with speciﬁc bone
cell lineages [13]. Myeloma cells held within niches are in a mitoti-
cally dormant state and this is maintained until they are released,
leading to the development of lytic bone disease in 90% of patients [2].
Dormancy allows single tumour cells establishing residency in bone
time to adapt to new environmental inﬂuences and to avoid the eﬀects
of drugs that target proliferating cells. The composition of the niche and
how this controls dormancy are not well understood, but there is evi-
dence that osteoblast (OB) lineage cells are important components.
Lytic bone disease associated with myeloma growth has, however, been
extensively studied [4] and colonised bone is characterised by reduced
osteoblastogenesis [5]. Osteolytic lesions arise in close proximity to the
tumour, suggesting that close contact between myeloma cells and bone
cells is required to inﬂuence bone remodelling [6]. A number of mo-
lecules have been implicated in the suppression of OB diﬀerentiation in
MM including the wingless-related integration site (Wnt)-signalling
inhibitor Dickkopf-related protein 1 (Dkk1) [7,8], secreted frizzled-re-
lated protein 2 (sFRP-2) [9,10], interleukin 7 (IL-7) [11,12] and he-
patocyte growth factor (HGF) [11], IL-3 [13,14] and sclerostin (SOST)
[15,16]. Antibodies to Dkk1 and SOST prevent the suppression of OB
diﬀerentiation and the development of lytic bone disease in vivo [7,17].
However, there are likely to be other regulators that contribute to OB
suppression in myeloma-induced bone disease [18].
In this study we aimed to identify other important factors involved
in the development of myeloma-induced bone disease, using the
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5TGM1 syngeneic murine model that develops osteolytic lesions in in-
ﬁltrated bones [19]. SOST and Sostdc1 are proteins with ~55%
homology in humans and both mediate suppression of bone morpho-
genic proteins (BMPs) and Wnt signalling [20]. In humans, the SOST
gene is located on chromosome 17 (Sost: chr 12 in mouse) and Sostdc1
on chromosome 7 (Sostdc1: chr 11 in mouse), the presence of the 2
genes being a result of past gene duplication where some division of
product function has evolved [20]. The eﬀective functional diﬀerences
between the 2 proteins appears to result from the distribution of the
expression of the genes with SOST being highly expressed in bone and
Sostdc1 being expressed in the kidney, tooth buds, and lung tissue.
Studies with knock-out mice show that loss of SOST expression results
in sclerosteosis in the axial skeleton, while there is no general bone
phenotype in Sostdc1 knock out mice apart from eﬀects in the teeth
including fusion and extra incisors [21]. The factors that control the
expression of these genes in speciﬁc locations are not fully understood
but it is suggested that BMPs/transforming growth factor βs and ﬁ-
broblast growth factors, as well as vitamin D signalling, regulate tran-
scription of both genes. The segregation of expression of each protein to
diﬀerent anatomical sites would suggest the need for control of action
and that inappropriate expression in tissues could have deleterious ef-
fects, as suggested by recent studies of the formation of digits in ex-
perimental animals [22].
As Sostdc1 is a putative inhibitor of OB diﬀerentiation that is not
expressed in adult bone, its presence in MM cells and in myeloma-in-
ﬁltrated bones would make it an interesting candidate in the context of
myeloma-induced bone disease. We have shown that MM and OB
lineage cells produce little Sostdc1 until they are in close proximity to
each other, when the protein is induced in both cell types. We subse-
quently evaluated the function of this protein in in vitro OB diﬀer-
entiation assays.
2. Materials and methods
2.1. Ethics statement
All procedures involving mice were conducted at the University of
Sheﬃeld, UK and were approved by the Home Oﬃce (PPL 40/3462)
and the University of Sheﬃeld's Animal Ethics Committee in ac-
cordance with the Animal [Scientiﬁc Procedures] Act 1986 and ARRIVE
guidelines.
2.2. Calvarial primary OB isolation and diﬀerentiation
Mouse primary OB progenitor cells were isolated from the calvarial
bones of 2 to 4 day old C57BLKaLwRij mice (Harlan, UK) using
Collagenase I (1 mg/ml, Sigma Aldrich) digestion solution as previously
described [23]. Isolated calvarial cultures were pooled and re-sus-
pended in complete Minimum Essential Medium alpha (MEMα) (In-
vitrogen, UK), containing 10% foetal calf serum (FCS), 100 units/ml
penicillin/100 μg/ml streptomycin. To diﬀerentiate OB progenitors,
cells were seeded (6000 cells/cm2) for 72 h in complete MEMα and
diﬀerentiated in osteogenic media (OGM): MEMα containing 4% FCS,
10mM β-glycerol phosphate and 50 μg/ml ascorbic acid. In preliminary
experiments, the basic growth/diﬀerentiation characteristics of the
primary osteoblast progenitors was evaluated over time courses up to
15 days post-addition of OGM. These studies showed that the cultures
could be maintained in 4% FCS and the presence of diﬀerentiation
markers were ﬁrst clearly observable on day 8 post treatment. This time
point was used for subsequent studies evaluating the eﬀects of Wnt3a,
BMP2, BMP7 or BMPs with and without antagonists/inhibitors.
2.3. Murine 5TGM1 myeloma cells
Murine 5TGM1 wildtype and 5TGM1-GFP expressing myeloma cells
(a kind gift from Dr. Oyajobi, University of Texas, San Antonio, USA)
were maintained in complete RPMI medium as previously described
[2].
2.4. Myeloma-OB co-cultures
OB progenitor cells were diﬀerentiated in culture plates or T175
ﬂasks for 8 days. On day 8 of diﬀerentiation, 5TGM1-GFP cells were
counted and co-cultured on the diﬀerentiating OB progenitors at a cell
density of 12,000 cell/cm2 similar to the estimated OB progenitor cell
number on day of 8 of diﬀerentiation. Cell seeding densities were
previously determined following OB progenitor growth curves sug-
gesting that OB cultures approximately doubled in DNA contents/cell
number by day 8 of diﬀerentiation (data not shown). 5TGM1-GFP/OB
progenitor cells were co-cultured for 24 h in complete RPMI media with
the diﬀerentiating OB progenitors at the same cell density as in cultures
of each cell line grown alone. This provided the opportunity for direct
contact between OB progenitors and 5TGM1 cells.
2.5. Sostdc1 detection in 5TGM1 and OB cells by immunoﬂuorescence
For immunoﬂuorescent detection of Sostdc1 in cell cultures, cell
adherence was facilitated using tissue culture grade poly-L-lysine
polymer reagent to coat all plates. 5TGM1 wildtype cells were ﬁxed
with 4% formalin and permeabilised with 0.1% Triton X for 10min
treated with 10% normal goat serum for 30min. Cells were stained with
anti-Sostdc1 (1 μg/ml anti-Sostdc1 rabbit polyclonal antibody, Abcam)
or an isotype control (1 μg/ml rabbit IgG polyclonal, Abcam), overnight
at 4 °C. The next day, cells were stained with an anti-rabbit secondary
antibody (6.6 μg/ml donkey anti-rabbit polyclonal IgG NorthernLights™
NL637-conjugated antibody, R&D Systems) for 1 h at room tempera-
ture. Cells were doubled stained with an anti-Syndecan-1 (CD138)
(6.6 μg/ml anti-Syndecan-1 mouse monoclonal FITC-conjugated anti-
body, Abcam), a plasma cell marker, or an isotype control (6.6 μg/ml
mouse IgG monoclonal FITC-conjugated antibody, eBiosciences) for 1 h.
4,6-Diamidino-2-phenylindole, dilactate (DAPI) was used to visualise
nuclear staining. Images of phase contrast, DAPI, CD138 and
Sostdc1staining were visualised simultaneously and represented as a
single stain on their own or merged as one image. Cellular staining was
observed by AF6000LX software (Leica DM16000 inverted microscope).
2.6. Flow cytometry and cell sorting
Cells from populations grown alone were detached, pelleted, ﬁxed
with 4% formalin and permeabilised in 0.1% Triton-X for 10min, be-
fore being treated with 10% normal donkey serum for 30min to reduce
non-speciﬁc binding of the secondary antibody. Cells were incubated
with an anti-Sostdc1 antibody (1 μg/ml anti-Sostdc1 rabbit polyclonal
antibody, Abcam) or isotype control antibody (1 μg/ml rabbit IgG
polyclonal antibody, Abcam) for 30min. Cell suspensions were in-
cubated with a ﬂuorescent-conjugated secondary antibody (2 μg/ml
donkey anti-rabbit polyclonal IgG NorthernLights™ NL637-conjugated
antibody, R&D Systems) for 30min. Flow cytometric analysis was
performed using the BD FACSCalibur™ platform and the data analysed
using the Cell Quest software. 5TGM1-GFP cells were detected via FL1
ﬂuorescence channel and OB progenitors through the FL4 ﬂuorescence
channel. Cell sorting of co-cultures was performed with the FACS Aria
ﬂow cytometer (BD Biosciences), in which 5TGM1-GFP and OB pro-
genitor co-cultures were separated into OB progenitor and 5TGM1-GFP
cell populations using GFP as a marker. In brief, 5TGM1-GFP and OB
progenitor cells cultured alone were sorted ﬁrst so that the correct
gating could be applied for each individual population. Cells from OB-
myeloma co-cultures were sorted into 1ml of RPMI for approximately
30min. 1ml sorted cell populations were then split into two tubes
containing 500 μl each; from which protein or RNA was extracted.
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2.7. In vivo study to obtain naïve and 5TGM1-inﬁltrated bone tissue
sections
All animals were housed in cages under standard conditions (12 h
light/dark cycle) and were healthy and pathogen free at the start of the
study. Once the study had commenced animals were monitored daily
for any unexpected adverse eﬀects. Animals were housed in groups and
the numbers per group were determined using power calculations based
on previous studies where reproducible statistical diﬀerences had been
demonstrated (2).
Male 78weeks old C57BL/KaLwRijHSD (C57BLKaLwRij) mice
(Envigo, UK) were randomised based on weight (1824 g) into 2 groups
and injected intravenously via the tail vein with either 100 μl PBS
(n=4, naïve, non-tumour bearing control group) or 2×106 5TGM1-
GFP expressing cells (n= 4, 5TGM1-bearing group). At the ﬁrst signs of
morbidity (after 3 weeks) all animals were anesthetized (100% w/v
isoﬂurane & 2% oxygen by inhalation) for cardiac bleeding and sacri-
ﬁced by cervical dislocation.
2.8. Detection of Sostdc1 in tissue sections by immunohistochemistry
Tibiae from naïve and 5TGM1-tumour bearing mice were ﬁxed in
4% paraformaldehyde, decalciﬁed, and paraﬃn embedded bone sec-
tions were cut. Antigen retrieval was done using 1:3 dilution of trypsin
enzyme for 10min. Sections were quenched with 10% H2O2 and
blocked with 10% goat serum solution (Invitrogen) for 30min before
incubation with rabbit anti-Sostdc1 antibody (1 μg/ml anti-Sostdc1
rabbit polyclonal antibody, Abcam) over night at 4 °C followed by goat
anti-rabbit biotinylated antibody (2 μg/ml goat anti-rabbit polyclonal
biotinylated antibody, R&D Systems) for 30min and incubation with
streptavidin solution (3 μg/ml, ThermoFisher) for 30min. Antibody-
antigen speciﬁc staining was developed with DAB Chromogen kit
(Vector Labs, UK). Tissue sections were counterstained with Gills hae-
matoxylin and images captured using an Aperio® ScanScope slide
scanner.
2.9. Western blot analysis
Protein was extracted from lysates of OB progenitor cells using a cell
mammalian lysis kit (Sigma, UK) and 10 μg loaded onto an SDS-PAGE
gels. Electrophoresed proteins were transferred onto a polyvinylidene
ﬂuoride membrane (Milipore, Bedford, USA) and nonspeciﬁc binding
sites blocked for 1 h with 3% bovine serum albumin (BSA). Blots were
probed overnight (4 °C) with polyclonal antibodies for Sostdc1 (3 μg/ml
anti-Sostdc1 rabbit polyclonal antibody, Abcam), phosphorylated
Smads 1, 5 and 8 proteins (3 μg/ml, Phospho-Smad1/Smad5/Smad8
rabbit polyclonal antibody, Cell Signalling), β-catenin (5 μg/ml, anti-β-
catenin rabbit polyclonal antibody, Abcam) and GAPDH (2 μg/ml, anti-
GAPDH mouse monoclonal antibody, Abcam). Membranes were in-
cubated with a HRP-conjugated secondary antibody speciﬁc to rabbit
(1 μg/ml, goat anti-rabbit IgG HRP-conjugated antibody, Life
Technologies Novex® or mouse (1 μg/ml, goat anti-mouse IgG HRP-
conjugated antibody, Santa Cruz) for 1 h. A chemiluminescent substrate
(Super Signal West Dura, Thermo Fisher) was used for detection of
speciﬁc proteins on X-ray ﬁlms (Kodak). Protein bands on X-ray ﬁlms
were analysed using the GS-710 Calibrated Imaging Densitometer
(Biorad) and the Quantity One software. An intensity threshold of 1 was
set on all lanes on the same blot and any background noise minimised
to obtain the relative intensity (RI) measure for individual bands.
Measurements of RI for target proteins were normalised to corre-
sponding GAPDH RI levels.
2.10. OB progenitor mineralisation
The mineralisation of OB progenitors treated with Sostdc1 in the
presence or absence of Wnt3a, BMP2 or BMP7 was assessed using
Alizarin red staining. This is a deﬁnitive functional marker of full os-
teoblast diﬀerentiation. OB cultures were ﬁxed in 100% ethanol for 1 h
and stained with 1% Alizarin red stain for 20min. Culture plates were
scanned (V800 Scanner, Epson UK) and the percentage area of miner-
alisation per well was quantiﬁed using ImageJ (http://imagej.nih.gov/
ij/; National Institutes of Health, Bethesda, MD, USA) as described
previously [24].
2.11. 5TGM1 and OB progenitor cells RNA isolation and RT-PCR
RNA was isolated from 5TGM1 and OB progenitor cells using the
ReliaPrep RNA cell Miniprep kit (Promega). Complementary DNA
(cDNA) was synthesized using 0.51 μg of total RNA and gene expres-
sion quantiﬁed using TaqMan® assays for quantitative RT-PCR (qRT-
PCR) analysis by SDS2.2.1. (Applied Biosystems): Runx2
(Mm00501584_m1), β-catenin (CTNNB1) (Mm00483039_ml) and β2
microglobin (B2M) (Mm00437762_m1). Absolute and relative gene
expression quantiﬁcation was normalised to the house keeping B2M
gene using the formula ΔCT=CTtarget− CThousekeeping. Presence of
speciﬁc PCR products was veriﬁed using 1.5% agarose-TBE gel elec-
trophoresis. Gels were loaded with 10 μl of DNA ladder (full range 100
BP Norgen) and 10 μl of PCR product and electrophoresis performed at
100 V for 30min. DNA fragments were inspected under UV light using
the Gel Doc XR+ System and the Quantity One software (Bio-Rad). PCR
products obtained from OB progenitor and 5TGM1 cultures and co-
cultures were sequenced using the Applied Biosystems' 3730 DNA to
verify Sostdc1 product identity (Sostdc1: forward 5-CCGTCATGCTTCT
CAGTTTC and Sostdc1: reverse 3-GCTGTCACACTCCAAGGGCC).
Sequencing results were analysed using FinchTv software version 1.4.0
and the base pair sequences were assessed for nucleotide similarities to
Sostdc1.
2.12. Interferometry kinetics for Sostdc1 interaction binding partners
The Bio-Layer Interferometry (BLI) (ForteBio) (www.ForteBio.com)
using Amine reactive 2nd generation (AR2G) biosensors were used to
evaluate interactions between recombinant Sostdc1 and low density
lipoprotein receptor-related protein 6 (LRP6), BMP2 or BMP7.
Interferometry data were globally ﬁt to a simple 1:1 Langmuir model
where one ligand molecule interacts with one analyte molecule and the
aﬃnities and rate constants calculated (Octet software, Version 6.4,
ForteBio). To produce a complete kinetic prolife for Sostdc1 and its
associated binding partner, the interaction was measured at multiple
analyte concentrations ranging from 0 to 100 μg/ml and the data used
for Langmuir model ﬁtting. The association and dissociation responses
were baseline corrected and processed using the Octet Software
(Version 6.4, ForteBio). The individual signal responses at each con-
centration were calculated and the measured aﬃnity of the interaction
KD (M) between the two proteins reported by the BLItz Pro™ software.
2.13. Statistical analysis
All data are presented as mean ± SEM of at least three experi-
ments. Statistical analysis was performed using a Students unpaired t-
test (Mann-Whitney if not parametric) and one-way ANOVA, using
Prism 6 software. *P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Sostdc1 levels are increased in myeloma and OB progenitor co-cultures
in both cell types
Our initial hypothesis was that Sostdc1 was produced by myeloma
cells and not by OB lineage cells. This was tested using the syngeneic
5TGM1 murine model of MM, which results in myeloma-induced bone
disease in mice, and in vitro in cultures of murine 5TGM1 myeloma cells
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and primary murine OB progenitor cells. Each cell type was grown
alone and in co-culture.
Flow cytometric analysis of cell cultures showed that ~5% of the
5TGM1 cells and< 1% of the OB progenitors grown alone were Sostdc1
positive but this increased signiﬁcantly to ~6% in the OB progenitors
isolated from co-cultures (P=0.043, Fig. 1A). To test whether Sostdc1
protein levels were increased in co-cultured cell populations, cells were
either grown alone or sorted from co-cultures into OB progenitor or
5TGM1 myeloma cell populations and Sostdc1 protein levels were
evaluated by Western blotting (Fig. 1B). These studies conﬁrmed the
presence of Sostdc1 in the co-cultured OB progenitor population in
comparison to OB progenitors cultured alone (P=0.028), where
Sostdc1 protein was near the limit of detection. There was also an in-
crease in Sostdc1 protein in the 5TGM1 cells sorted from the co-cultures
compared to 5TGM1 cells grown alone, although this was not statisti-
cally signiﬁcant.
To test whether OB progenitor diﬀerentiation was suppressed by
5TGM1 derived Sostdc1, the levels of expression of the OB marker
Runx2 was evaluated in populations grown alone and in co-
culture± 1.5 μg/ml anti-Sostdc1 neutralising antibody. Data showed
Fig. 1. Sostdc1 protein levels are increased by myeloma cells-OB progenitor interaction and blocking Sostdc1 reverses myeloma-induced suppression of OB dif-
ferentiation: (A) Flow cytometry analysis of 5TGM1-GFP cells and OB progenitors (alone or in co-culture) for the expression of murine Sostdc1 protein. (B) Western
blot analysis of cell lysates from 5TGM1-GFP cells and OB progenitors (alone or in co-culture) illustrating the level of Sostdc1 protein. The relative intensity (RI) of
the Sostdc1 protein band was normalised to the RI of corresponding GAPDH protein band in the same sample. HK2 cells were used as a positive control for Sostdc1
expression. (C) Quantitative RT-PCR analysis of Runx2 gene expression in 5TGM1-GFP cells and OB progenitors (alone or in co-culture), in the absence or presence of
anti-Sostdc1 antibody. N=3 independent experiments, Student t-test, One-way ANOVA, *P < 0.05.
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Fig. 2. Sostdc1 was upregulated in 5TGM1 tibiae sections and 5TGM1-OB progenitor co-cultures: Immunoassays and end-point PCR were performed to detect
Sostdc1 in 5TGM1-GFP cells and diﬀerentiating OB progenitors (alone and in co-culture). (A) Immunohistochemistry for Sostdc1 in naïve and 5TGM1-inﬁltrated tibia
sections. Arrows indicate osteoblasts (naïve, left image) or tumour cells (5TGM1, right image). (B) Confocal microscopy for Sostdc1 in OB progenitors cultured alone
(i) 5TGM1-GFP (CD138 positive cells) cultured alone (ii) or in co-culture (iii). 5TGM1/OB progenitors in contact highlighted in white squares. (C) High power ﬁeld of
co-cultures stained with DAPI and with antibodies for CD138/Sostdc1 merged. Isolated and associated cells are highlighted. All ﬁgures are representative of 3
independent experiments.
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that 5TGM1 cells cultured alone did not produce detectable levels of
Runx2 (Fig. 1C). Runx2 expression was detected in diﬀerentiating OB
progenitors cultured alone and expression was reduced in these cells in
the presence of 5TGM1 cells (P=0.023). Treatment of 5TGM1-OB
progenitor co-cultures with anti-Sostdc1 antibody reversed this eﬀect,
restoring Runx2 levels in OB progenitors (P=0.028).
Immunohistochemistry was used to compare the presence of
Sostdc1 protein expression in naïve (non-tumour) murine tibiae sec-
tions to those inﬁltrated with 5TGM1 cells. Sostdc1 protein was present
in 5TGM1-inﬁltrated tibiae sections and absent in sections obtained
from naive animals (Fig. 2A). Sostdc1 staining was strongest within the
5TGM1 cells themselves in these sections, although it was diﬃcult to
identify any OB cells in close proximity to 5TGM1 colonies at the time
points studied.
Immunoﬂuorescent microscopy was used to determine the presence
of Sostdc1 protein in OB progenitor cells and 5TGM1 cells cultured
alone and in co-culture. OB progenitors stained with anti-Sostdc1 were
negative, whilst 5TGM1 cells were weakly positive for staining with this
antibody (Fig. 2B). Co-culture of 5TGM1 cells with OB progenitor cells
resulted in clear Sostdc1 staining in both cell types. Sostdc1 staining in
these co-cultures appeared to be both intracellular and membrane
bound (Fig. 2B & C). Staining for Sostdc1 was distinct and intense
where there was direct contact between the 5TGM1 cells and OB pro-
genitor cells. In all cultures, there was no staining with the isotype
control antibodies (results not shown).
3.2. Recombinant Sostdc1 suppressed Wnt and BMP-induced diﬀerentiation
and mineralisation in OB progenitors
Diﬀerentiating OB lineage cells isolated from the calvaria of neo-
natal mice and maintained in cell culture in low levels of FCS were
challenged with murine recombinant Sostdc1. Quantitative RT-PCR was
used to assess the eﬀect of Sostdc1 on Wnt and BMP-induced Runx2
gene expression (Fig. 3). The eﬀect of Dkk1 on Wnt3a-induced Runx2
gene expression and noggin on BMP-induced expression were also as-
sessed, as they are known Wnt and BMP antagonists respectively. The
optimal concentration of the recombinant proteins used as stimulants or
antagonists of the Wnt/BMP pathway was determined via dose response
viability assays (data not shown). The IC50 and Hill Slope of the dose-
response curve were used to calculate the concentration at which 50%
of OB progenitor cells survived following treatment with a stimulant or
antagonist. These studies showed that on their own, Sostdc1, noggin
and Dkk1 had no eﬀect on Runx2 gene expression (Fig. 3). Wnt3a on its
own induced approximately two-fold increase in Runx2 gene expression
(P=0.035), and Sostdc1 (250 ng/ml) inhibited this Wnt3a-induced
Runx2 gene expression (P=0.005, Fig. 3A). Dkk1 had no signiﬁcant
eﬀect on Wnt-induced Runx2 gene expression during OB progenitor
diﬀerentiation. BMP2 induced Runx2 gene expression of OB progenitor
diﬀerentiation and Sostdc1 inhibited this inductive eﬀect (P=0.005,
Fig. 3B). Noggin had a similar eﬀect to Sostdc1, down regulating BMP2-
induced Runx2 gene expression levels in diﬀerentiating OB progenitors
(P=0.049, Fig. 3B). BMP7 induced Runx2 expression in the early
stages of OB progenitor diﬀerentiation (P=0.013) and Sostdc1 was
able to signiﬁcantly reverse this eﬀect (P=0.008, Fig. 3C). In the
presence of BMP7, noggin had a similar suppressive eﬀect to Sostdc1 on
Runx2 gene expression in the early stages of OB progenitor diﬀer-
entiation (P=0.008, Fig. 3C).
Alizarin Red staining was used to investigate the eﬀect of Sostdc1 on
OB progenitor mineralisation in the presence of Wnt3a, BMP2 or BMP7.
Wnt3a (50 ng/ml) signiﬁcantly stimulated mineralisation of OB pro-
genitor cells (P < 0.0001) and addition of Sostdc1 to Wnt3a treated OB
progenitors resulted in a signiﬁcant reduction of OB progenitor mi-
neralisation (P=0.016, Fig. 3D). Dkk1 had no suppressive eﬀects on
Wnt3a-induced mineralisation under the same experimental conditions.
Analysis of Alizarin Red staining showed that both BMP2 and BMP7
induced OB diﬀerentiation (P=0.002, Fig. 3E, P=0.001 Fig. 3F,
respectively) compared to controls. The BMP2 and BMP7-induced cal-
cium mineralisation was inhibited in the presence of Sostdc1
(P=0.044, Fig. 3E, P=0.019 Fig. 3F). The addition of noggin in the
presence of BMP had no signiﬁcant suppressive eﬀects on BMP2- or
BMP7-induced mineralisation under the same experimental conditions.
3.3. Sostdc1 inhibited acute Wnt and BMP-induced intracellular signalling
in OB progenitors
To determine the eﬀect of Sostdc1 on Wnt and BMP-induced in-
tracellular signalling, the status of downstream signalling molecules in
these pathways were separately assessed following addition of re-
combinant Sostdc1 treatment to OB cultures. OB progenitor cells were
diﬀerentiated and stimulated with single or combination protein
treatments for 20min, after which OB progenitor cultures were lysed.
To assess the eﬀect of Sostdc1 on Wnt-induced intracellular signalling,
β-catenin protein levels were determined using Western blot analysis.
The eﬀect of Sostdc1 on BMP2- and BMP7-induced downstream sig-
nalling was further analysed via quantiﬁcation of phosphorylated levels
of Smads 1, 5 and 8 proteins. Dkk1 (100 ng/ml) and noggin (100 ng/ml)
were used as known inhibitors of BMP signalling.
Western blot analysis showed that in the presence of Wnt3a, Sostdc1
suppressed β-catenin protein levels in OB progenitor cultures
(P=0.019, Fig. 4A). Dkk1 protein had a similar suppressive eﬀect on
Wnt-induced β-catenin protein levels (P=0.012). Densitometry data
showed that BMP2 and BMP7 both induced Smads 1, 5 and 8 protein
levels and Sostdc1 reversed this eﬀect (BMP2 P=0.045, Fig. 4B; BMP7
P=0.0002, Fig. 4C). Similarly, noggin also down-regulated BMP-in-
duced Smads 1, 5 and 8 protein levels in the early stages of OB pro-
genitor diﬀerentiation (BMP2 P=0.037, Fig. 4B; BMP7 P < 0.0001,
Fig. 4C).
The kinetics of Sostdc1 with potential binding partners was assessed
using interferometry. The binding aﬃnity (KD) of Sostdc1 for the Wnt
receptor recombinant murine LRP6 was 8.502 · 10−10M KD, Sostdc1
for BMP2 was 9.569 · 10−9M KD and Sostdc1 for BMP7 was calculated
at< 1.0 · 10−12M KD (Fig. 4D). The aﬃnity of Sostdc1 for the LPR6
receptor protein was one-fold higher compared to the aﬃnity of
Sostdc1 for BMP2 ligand protein. This data show that Sostdc1 had the
highest binding aﬃnity for the ligand BMP7 protein out of all three
Sostdc1-protein interactions. The Sostdc1 protein had a three-fold
higher binding aﬃnity for BMP7 compared to LRP6.
3.4. Sostdc1 down regulated Wnt-BMP signalling crosstalk in OB
progenitors
In studies to determine potential crosstalk between BMP and Wnt
signalling pathways, the eﬀects of Wnt3a alone on β-catenin (CTNNB1)
expression was initially assessed. The levels of CTNNB1 and B2M ex-
pression were quantiﬁed by qRT-PCR in OB progenitor cells. Wnt3a
(50 ng/ml) signiﬁcantly increased CTNNB1 expression in diﬀerentiating
OB progenitors (P=0.034, Fig. 5Ai). In the same experiments, Sostdc1
(250 ng/ml), but not Dkk1 signiﬁcantly reduced Wnt3a-induced
CTNNB1 levels (P=0.0142). The CTNNB1 expression by OB progeni-
tors was not aﬀected in the presence of Sostdc1 or Dkk1 alone. Further
analysis of CTNNB1 expression in BMP-stimulated OB progenitors
showed that BMP2 (30 ng/ml) and BMP7 (30 ng/ml) induced CTNNB1
gene expression of OB progenitor diﬀerentiation on a similar level to
that observed in cultures treated with Wnt3a (P=0.006 and
P=0.025). In the presence of BMP2, Sostdc1 reduced CTNNB1 levels
in OB progenitors (P < 0.0001, Fig. 5Aii). Noggin (100 ng/ml) also
suppressed BMP2-induced CTNNB1 levels in OB progenitors
(P=0.006). BMP7-induced CTNNB1 expression was also reduced in
the presence of Sostdc1 (P=0.010) and noggin reduced BMP7-induced
CTNNB1 transcript levels (P=0.008, Fig. 5Aiii).
Western blot analysis was performed to determine whether Wnt3a
increased phosphorylated Smads 1, 5 and 8 protein levels downstream
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Fig. 3. Sostdc1 reduces OB progenitor diﬀerentiation induced by Wnt and BMP ligands: Diﬀerentiating OB progenitors were treated with Wnt3a, BMP2 or BMP7.
Dkk1 and noggin were used as known Wnt and BMP antagonist controls, respectively. Quantitative RT-PCR of Runx2 mRNA relative expression to B2M in diﬀer-
entiating OB progenitors treated with Wnt3a (A), BMP2 (B) and BMP7 (C) alone or in the absence or presence of Sostdc1, Dkk1 or noggin. Mineralisation of OB
progenitors treated with Wnt3a (D), BMP2 (E) and BMP7 (F) in the absence or presence of Sostdc1, Dkk1 or Noggin. Results are expressed as the % area of the well
that was mineralised. N=4 independent experiments. One-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001.
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of the BMP signalling pathway in diﬀerentiating OB progenitors. Wnt3a
(50 ng/ml) acutely induced Smads 1, 5 and 8 protein phosphorylation
in diﬀerentiating OB progenitors (P=0.032, Fig. 5B). In the same ex-
periments, Sostdc1 suppressed Wnt3a-induced phosphorylated Smads
1, 5 and 8 protein levels (P < 0.029) to a similar extent as Dkk1
(P=0.037).
The level of β-catenin in diﬀerentiating OB progenitors was assessed
following stimulation with BMP2 or BMP7 proteins. Both BMP2 and
BMP7 were able to signiﬁcantly induce β-catenin protein levels
(P < 0.05). Sostdc1 and noggin both signiﬁcantly suppressed BMP2
and BMP7-induced β-catenin in OB progenitor diﬀerentiation
(P < 0.05) and β-catenin protein levels were not aﬀected in the pre-
sence of Sostdc1 or noggin alone.
4. Discussion
Our studies, using a murine model of MM, show that Sostdc1 is
present in the bone marrow of tibiae inﬁltrated with myeloma cells but
not in the bone marrow of non-tumour bearing (naïve). The antibody
used in these analyses and in studies with cell cultures to detect Sostdc1
was speciﬁc for this protein and was raised to a unique epitope not
present on sclerostin. The presence of Sosdc1 in myeloma-inﬁltrated
bones is novel and unexpected ﬁnding as this protein is not normally
expressed in bone [20]. While immunohistochemistry showed protein
expression within the 5TGM1 myeloma cells, it should be noted that the
bones examined were well inﬁltrated at the time of sacriﬁce, a point
where there were few visible osteoblastic cells remaining near to the
myeloma colonies. This is not surprising since our studies have shown
that recombinant Sostdc1 has potent eﬀects in suppressing OB diﬀer-
entiation, speciﬁcally interfering with known pathways that drive this
process. We initially thought that the myeloma cells themselves were
the sole source of this protein in lesions. However, our in vitro studies
showed that myeloma cells produced very low levels of Sostdc1 and the
protein is undetectable in OB progenitor cells, when these cells are
grown alone. In co-cultures, Sostdc1 expression and protein levels were
induced in both cell types. We showed that in the co-culture studies, a
marker of OB diﬀerentiation Runx2 gene expression, was inhibited by
the presence of 5TGM1 myeloma cells and that this eﬀect could be
reversed by co-treatment of cultures with a blocking antibody for
Sostdc1, indicating that the levels of Sostdc1 generated in co-cultures
are biologically active. Together these ﬁndings support the concept that
Sostdc1 produced by interacting 5TGM1 and OB lineage cells in vivo,
would induce the loss of OBs from bone. This alteration in the bone
microenvironment may have eﬀects on MM interactions with bone
populations aﬀecting myeloma cell survival and dormancy [1]. Inter-
estingly, a number of studies have already shown that BMPs induce
apoptosis and suppress proliferation of human myeloma cells [2527].
Our studies would imply that Sostdc1 present in myeloma-inﬁltrated
bones could suppress the above reported eﬀects on apoptosis in MM by
competitive binding to BMPs.
In in vitro studies we tested the hypothesis that Sostdc1 antagonises
Wnt and BMP-induced diﬀerentiation and acute signalling in OB pro-
genitors. Our data supported this hypothesis and showed that Sostdc1
reduced Wnt3a, BMP2 and BMP7-induced Runx2 gene expression and
calcium mineralisation of OB progenitors. These ﬁndings are similar to
those of Laurikkala et al., which found the mouse orthologue of Sostdc1
inhibited both Wnt and BMP-induced MC3T3-E1 diﬀerentiation [28].
Interestingly though in our studies, Dkk1 had no signiﬁcant eﬀect on
Wnt3a stimulated Runx2 expression. However, since Sostdc1 acts on
osteoblast progenitors and Dkk1 is secreted from mature osteoblasts, to
inhibit Wnt signalling of osteoblast precursors [29], it is entirely pos-
sible that the time points that we see signiﬁcant suppressive eﬀects of
Sostdc1 diﬀer from those of Dkk1.
We also showed that in the presence of Wnt3a, Sostdc1 reduced β-
catenin levels in OB progenitor cells. The suppression of Wnt3A induced
a reduction in total β-catenin protein levels as well as decreases in the
levels of activated (phosphorylated) forms of this protein in cultures of
human osteoblastic cells in the presence of Sostdc1 (Supplementary
Fig. 1). Similarly, the addition of Sostdc1 in the presence of BMP li-
gands reversed BMP-induced Smad phosphorylation. These observa-
tions suggest that the activities of Sostdc1 modulate both signalling
systems involved in OB diﬀerentiation. Other studies have demon-
strated a synergistic relationship between BMP and β-catenin during OB
diﬀerentiation [3032]. Secreted molecules such as cerberus and
sclerostin, also inhibit OB activity by binding BMP/Wnt ligands [33]
and receptors [34]. However, the regulatory role of Sostdc1 on Wnt-
BMP crosstalk in diﬀerentiating OB progenitors has not been studied.
Our data showed that treatment of diﬀerentiating OB with Wnt3a in-
creased Smad phosphorylation and treatment with BMP2/7 enhanced
Wnt signalling via β-catenin modulation. Similarly Zhang et al. reported
that Wnt3a increased transcriptional activity of a BMP/Smad reporter
and that co-treatment with a known inhibitor of BMP signalling,
noggin, inhibited this eﬀect [34]. Here we have shown that Sostdc1
negatively aﬀected Wnt-BMP cooperation mediated by β-catenin-and
regulatory-Smads in OB progenitors.
Lintern and Guidato et al. showed Sostdc1 may have separate do-
mains for Wnt and BMP interaction, showing the independent binding
capabilities of Sostdc1 to LRP6 receptor and BMP ligands [35]. Our
interferometry data showed recombinant Sostdc1 had a highest binding
aﬃnity for BMP7, followed by LRP6 and lastly BMP2. These ﬁndings
provide direct evidence that Sostdc1 has the capacity to interact with
both BMP and Wnt signalling systems but may suggest selectivity for
individual components although it can act as an eﬀective antagonist for
both pathways.
Our studies suggest Sostdc1 antagonises Wnt-BMP signalling in the
early phase of OB diﬀerentiation. In vitro studies have suggested that
Dkk1 mainly aﬀects the function of mature OB cells and drives plur-
ipotent cells to diﬀerentiate to OB lineages [36]. Rawadi et al. de-
monstrated that blocking Wnt/LRP5 signalling with Dkk1 in me-
senchymal stem cells inhibited BMP2-induced alkaline phosphatase
activity [32]. Dkk1 has also been shown to target BMPRIA, a BMP re-
ceptor in OBs, and mediate suppression of BMP signalling in mature
bone. As Sostdc1 and Dkk1 both target the LRP/Frz-Wnt receptors and
regulate Wnt-BMP crosstalk in OB progenitors, either molecule may be
active at various stages in the development of myeloma-induced lytic
bone disease: Dkk1 having a role in targeting mature OB cells, while
Sostdc1 aﬀects the maturation of OB progenitors.
In conclusion, we have shown that Sostdc1 is a potent suppressor of
OB diﬀerentiation in vitro and that the production of this protein in OBs
and myeloma cells is induced when these cells interact with each other.
This is the ﬁrst report showing the induced production of this protein by
MM-OB interactions. These ﬁndings may suggest that targeting the in-
duced production of Sostdc1 in MM inﬁltrated bones could have ben-
eﬁts in suppressing disease progression in MM.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bone.2019.02.012.
Fig. 4. Sostdc1 reduces Wnt/BMP signalling and binds to LRP6, BMP2 and BMP7 proteins: Diﬀerentiating OB progenitors were treated with Wnt3a, BMP2 or BMP7 in
the absence or presence of recombinant murine Sostdc1 protein for 20min. Western blot analysis and quantiﬁcation of cell lysates from OB progenitors stimulated by
Wnt3a (A), BMP2 (B) or BMP7 (C) in the absence or presence of Sostdc1, Dkk1 or noggin illustrating the level of β-catenin (A) or Phospho-Smads 1, 5 & 8 (B and C).
Kinetic analysis and binding aﬃnity of Sostdc1 binding to LRP6, BMP2 and BMP7 using the Blitz Analysis system. (D) 100 μg/ml of Sostdc1 bound to rmLRP6, BMP2
and BMP7, and had the highest binding aﬃnity for BMP7. N=4 independent experiments. One-way ANOVA, *P < 0.05, **P < 0.01. ***P < 0.001.
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Fig. 5. Sostdc1 inhibits BMP-induced β-catenin (CTNNB1) expression in diﬀerentiating OB progenitors: (A) Quantitative RT-PCR of CTNNB1 in OB progenitors
cultured with Wnt3a, BMP2 or BMP7 in the presence or absence of Sostdc1, Dkk1 or Noggin. Data represent the relative expression of CTNNB1 to B2M. (B) Western
blot analysis of cell lysates from OB progenitors stimulated by Wnt3a (i), BMP2 (ii) or BMP7 (iii) in the absence or presence of Sostdc1, Dkk1 or noggin illustrating the
level of Phospho-Smads 1, 5 & 8 (i) or β-catenin (ii and iii). N=4 independent experiments, One-way ANOVA, *P < 0.05, **P < 0.01 and ***P < 0.001.
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